Puma Biotechnology Stock Rating Reaffirmed by Citigroup Inc. (PBYI)

Share on StockTwits

Puma Biotechnology (NASDAQ:PBYI)‘s stock had its “buy” rating restated by equities researchers at Citigroup Inc. in a research report issued on Tuesday. They currently have a $99.00 price target on the stock, down from their previous price target of $123.00. Citigroup Inc.’s target price points to a potential upside of 59.27% from the company’s current price.

Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 62.16 on Tuesday. Puma Biotechnology has a 52 week low of $33.70 and a 52 week high of $143.65. The stock has a 50-day moving average of $64.14 and a 200-day moving average of $94.93. The company’s market cap is $1.872 billion.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Monday, May 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.19. On average, analysts predict that Puma Biotechnology will post $-2.56 earnings per share for the current fiscal year.

Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Northern Oil & Gas Downgraded by Zacks to “Neutral”
Northern Oil & Gas Downgraded by Zacks to “Neutral”
NVR Earns “Outperform” Rating from JMP Securities
NVR Earns “Outperform” Rating from JMP Securities
Oasis Petroleum Receives Buy Rating from Wunderlich
Oasis Petroleum Receives Buy Rating from Wunderlich
Ocwen Financial Corp Rating Lowered to Hold at Evercore Partners
Ocwen Financial Corp Rating Lowered to Hold at Evercore Partners
Oneok Partners PT Lowered to $54.00
Oneok Partners PT Lowered to $54.00
SandRidge Permian Trust Rating Lowered to Underperform at Zacks
SandRidge Permian Trust Rating Lowered to Underperform at Zacks


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.